Hays Advisory’s Anika Therapeutics ANIK Stock Holding History

Hays Advisory’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-29	Closed	-$1K	–	81
2018 Q1	$1K	Buy	+29	New	+$1.64K	﹤0.01%	120

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Hays Advisory's ANIK Position: Q2 2018 in Review

Hays Advisory sold out of Anika Therapeutics (ANIK) in Q2 2018, closing a stake of 29 shares — an estimated $1K sold.

Hays Advisory first reported a position in ANIK in Q1 2018 and held it in 1 quarter. The position peaked at $1K in Q1 2018. 170 funds tracked by Wall St. Rank hold ANIK as of Q2 2018.

Hays Advisory reported no remaining Anika Therapeutics position as of Q2 2018 after selling out during the quarter.
Hays Advisory sold 29 Anika Therapeutics shares in Q2 2018, an estimated $1K.
Hays Advisory first reported a position in Anika Therapeutics in Q1 2018 and held it in 1 quarter.
Hays Advisory's Anika Therapeutics position peaked at $1K in Q1 2018.
170 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2018.

Based on Hays Advisory's 13F filing for Q2 2018, filed 23 Jul 2018.